Novartis to pay $1.53 billion for dermatology firm

Thursday 3 May 2012

Novartis is to significantly expand its Sandoz generics business with the acquisition of Fougera Pharmaceuticals Inc, a US specialty dermatology business with net 2011 sales of $429 million. Novartis is paying $1.53 billion in cash.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland